preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedmidhigh inflation risk
Roseomonas
atopic dermatitis
Roseomonas has meaningful literature visibility in atopic dermatitis, but the current evidence mix suggests a substantial risk of overclaiming.
Roseomonas has a broader but less central evidence footprint in atopic dermatitis, with support coming from indirect, review, or preclinical literature.
roseomonas
Credibility score
20
Human translation
2/5
Reproducibility
4/5
Novelty
4/5
Actionability
1/5
Credibility 20Human translation 2/5Reproducibility 4/5Novelty 4/5Actionability 1/5
Why this scores the way it does
- meaningful supporting human literature
Main caveats
- preclinical evidence outweighs human evidence
- limited central evidence
Internal review flags
1 flagsPrimary central evidence
3 papersLiving symbiotic bacteria-involved skin dressing to combat indigenous pathogens for microbiome-based biotherapy toward atopic dermatitis.
2023Bioactive materials
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteria.
2023Science advances
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Co-occurrence network analysis reveals the alterations of the skin microbiome and metabolome in adults with mild to moderate atopic dermatitis.
2024mSystems
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Supporting primary evidence
3 papersMicrobial manipulation in atopic dermatitis.
2022Clinical and translational medicine
Human primary paper with plausible association relevance to the disease context.
De novo assembly of Roseomonas mucosa isolates from healthy human volunteers used to treat atopic dermatitis.
2023Microbiology resource announcements
Human primary paper with plausible association relevance to the disease context.
De novo assembly of Roseomonas mucosa isolated from patients with atopic dermatitis.
2023Microbiology resource announcements
Human primary paper with plausible association relevance to the disease context.
Preclinical supporting evidence
8 papersFirst-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis.
2018JCI insight
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Differing Virulence of Healthy Skin Commensals in Mouse Models of Infection.
2018Frontiers in cellular and infection microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Therapeutic responses to Roseomonas mucosa in atopic dermatitis may involve lipid-mediated TNF-related epithelial repair.
2020Science translational medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Assessing the effects of common topical exposures on skin bacteria associated with atopic dermatitis.
2021Skin health and disease
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Assessing microbial manipulation and environmental pollutants in the pathogenesis of psoriasis.
2022Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Diisocyanates influence models of atopic dermatitis through direct activation of TRPA1.
2023PloS one
Disease-relevant preclinical or model-based paper useful as supporting evidence.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis.
2024Dermatology (Basel, Switzerland)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Spatial modeling connecting childhood atopic dermatitis prevalence with household exposure to pollutants.
2024Communications medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
5 papersThe microbiome in patients with atopic dermatitis.
2019The Journal of allergy and clinical immunology
Relevant review or meta-analysis for the signal-disease area.
Update on the Pathogenesis and Therapy of Atopic Dermatitis.
2021Clinical reviews in allergy & immunology
Relevant review or meta-analysis for the signal-disease area.
Skin microbiome of atopic dermatitis.
2022Allergology international : official journal of the Japanese Society of Allergology
Relevant review or meta-analysis for the signal-disease area.
Environmental and behavioral mitigation strategies for patients with atopic dermatitis.
2024JAAD international
Relevant review or meta-analysis for the signal-disease area.
Skin Microbiome Dynamics in Atopic Dermatitis: Understanding Host-Microbiome Interactions.
2025Allergy, asthma & immunology research
Relevant review or meta-analysis for the signal-disease area.